AI assistant
Sending…
Vaxcyte, Inc. — Director's Dealing 2024
Apr 19, 2024
31100_dirs_2024-04-19_498cf87a-bca7-43b6-9d25-95bb6e59d8bd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2024-04-17
Reporting Person: Wassil Jim (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-17 | Common Stock | M | 3551 | $5.35 | Acquired | 221840 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-04-17 | Stock Option (right to buy) | $5.35 | M | 3551 | Disposed | 2030-04-17 | Common Stock (3551) | Direct |
Footnotes
F1: Stock Option is fully vested and exercisable.
More from Vaxcyte, Inc.
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 19
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Mar 3
Capital/Financing Update
2026
Feb 24